⏳ CheckMate 238: 9 años de seguimiento Los datos finales confirman que nivolumab mantiene un beneficio sostenido en RFS vs. ipilimumab en melanoma. ❗ Pero sin beneficio claro en OS, y con la neoadyuvancia ganando terreno… 💡 ¿Adyuvancia o neoadyuvancia? 📥 Lee el análisis 👉 f.mtr.cool/azlofxbohn #Oncología #Melanoma #CheckMate238 #Nivolumab #Inmunoterapia #Neoadyuvancia #Adyuvancia #OncoBites #ESMO2025

New findings from the #CheckMate238 trial highlight #nivolumab's superior long-term efficacy over #ipilimumab in treating advanced melanoma. #ESMO25 hubs.li/Q03PdNxq0

Adjuvant anti-PD-1 therapy in stage II #Melanoma: treatment decisions are complex. Experts discuss #CheckMate238 results and how they individualize care. Featuring @DrBetofMDPhD, Amaria, and @DrSapnaPatel. bit.ly/4377hVt #Immunotherapy @MDAndersonNews

5/14 Adjuvant therapy SOC in resectable stage III-IV dz (CheckMate238, KEYNOTE054, COMBI-AD); yet stage IIB/C survival similar to IIIA/B and not routinely tx #ACSCancerChat

Atualização Fase 3 CheckMate238 #ESMO20 @TheLancetOncol No seguimento de 4 anos, Nivolumabe adjuvante mantém redução da SLR qndo comparado a Ipilimumabe no Melanoma IIIB-C e IV, com melhor tolerância thelancet.com/journals/lanon… #MOCnaESMO #melanoma #Immunotherapy @MelanomaSarcoma

Finally OS data from CheckMate238. Seeing the OS identical curves, is the PFS benefit of nivolumab vs. ipilimumab (primary endpoint) enough in the adjuvant setting? Would we see different results with placebo in the comparator arm? #ESMO20 #Melanoma

#SkinCancer updates at #ESMO20: Jeffrey Weber of @nyulangone discusses the 4-year results from the #CheckMate238 trial Watch the full video here: 👉bit.ly/3iMxNdi👈 @VJOncology @myESMO @OncoAlert #OncoAlert #CTsm #MelSM #SkcSM

Reminder : why access to #immunotherapy (here Nivo) for ALL Stage III #melanoma patients in Ireland matters - #Checkmate238 shows 50% improvement of relapse free survival for Nivo patients v placebo #accesstomedicines #twotiersystem #nivolumab #eado2019

VIDEO: @PAscierto discusses #Melanoma advancements: #Immunotherapy in the #Adjuvant setting: ow.ly/jcWg30lvEjA @ASCO #ASCO18 #SkinCancer #Melsm #CheckMate238 #ClinicalTrials #CTSM #ImmunoOnc #Antibodies #CheckpointInhibitors #TargetedTherapy #Skcsm #Immunology

#Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS @PAscierto @VJOncology #CheckMate238 bit.ly/2B8Encw

CheckMate238 update - by J Weber @ASCO - Sustained efficacy benefit for adjuvant NIVO vs IPI in resected stage III/IV melanoma, regardless of stage, PD-L1, or BRAF #ASCO2018 @ClevelandClinic @CleClinicMD #CleClinicCancer

Results of adjuvant studies in melanoma #checkmate238 (nivo vs. ipi) and #keynote054 (pembro vs. placebo) support “Coke and Pepsi” theory as far checkpoint inh bigots are concerned #AACR2018

News: Our #ESMO17 coverage continues-#CheckMate238 pits adjuvant nivolumab against ipilimumab in metastatic melanoma bit.ly/2fkCLiH

Weber on #Checkmate238 bit.ly/2y5j6Lx #ESMO17 @nyulangone @PAscierto @OmidHamidMD @BernardAFox @NIBITSIENA @lucadf @MandalaMario

Presidential Symp at #ESMO17: Closing Remarks by Dr. Dummer, Discussant of Checkmate238(@NEJM), Adj IT 4 Adv #Melanoma #Immunoonc #melsm

Jeffrey Weber of @nyulangone on #CheckMate238 in #melanoma #skincancer #ESMO17

Weber on #checkmate238 #ESMO17 @PAscierto @OmidHamidMD @BernardAFox @RecentiProgMed @Melanoma_doctor @ImmunoterapiaSi

Opdivo Demonstrates Superior Recurrence-Free Survival Vs Yervoy forPts w/ High-Risk Melanoma in P3 CheckMate238 $BMY finance.yahoo.com/news/opdiv…

Another P3 #CheckMate238 trial of #Opdivo meets PE #RFS vs #Yervoy in adj #melanoma Rivalry continues for #Keytruda news.bms.com/press-release/c…